MARKET

EXAS

EXAS

Exact Sciences Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

47.89
-4.11
-7.90%
After Hours: 48.40 +0.51 +1.06% 19:25 05/24 EDT
OPEN
51.39
PREV CLOSE
52.00
HIGH
51.39
LOW
47.50
VOLUME
1.45M
TURNOVER
0
52 WEEK HIGH
133.99
52 WEEK LOW
46.15
MARKET CAP
8.43B
P/E (TTM)
-11.0885
1D
5D
1M
3M
1Y
5Y
Here's Why You Should Hold on to Exact Sciences (EXAS) Stock
Investors are optimistic about Exact Sciences (EXAS) on impressive Q1 results and a bullish 2022 outlook.
Zacks · 1d ago
Why Ark Innovation ETF Hit 52-Week Lows Today
ARK Innovation ETF (ARCA:ARKK) is making new 52-week lows on Monday, led by sharp declines in the top holdings of Ark's flagship fund.
Benzinga · 05/09 19:40
Illumina Stock Plunges Despite Strong Results, Gene-Sequencing Sales
The company reaffirmed that it wants to increase sales in blood-based cancer screening and new drug discovery.
Barrons.com · 05/06 14:58
Exact Sciences to participate in May investor conference
Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that company management will participate in the following conference and invited investors to participate by webcast.
PR Newswire · 05/02 10:00
Exact Sciences's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, Exact Sciences's (NASDAQ:EXAS) reported sales totaled $486.57 million. Despite a 17.98% increase in earnings, the company posted a loss of $180.94 million.
Benzinga · 04/28 13:50
Exact Sciences Highlights Updated, Expanded American Society Of Clinical Oncology Guidelines That Recommend Use Of Co.'s Oncotype Breast Recurrence Score Test
Oncotype DX® receives highest rating of all multigene tests in the guidelines for quality of evidence and strength of recommendation New guidelines reflect highest level of evidence from independent RxPONDER
Benzinga · 04/28 13:05
Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients
Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence Score® test in early-stage breast cancer patients has been expanded by the American Society of Clinical ...
PR Newswire · 04/28 13:00
SVB Leerink Maintains Outperform Rating for Exact Sciences: Here's What You Need To Know
SVB Leerink has decided to maintain its Outperform rating of Exact Sciences (NASDAQ:EXAS) and lower its price target from $130.00 to $95.00. Shares of Exact Sciences are trading up 7.86% over the last 24 hours, at $63.24 per share.
Benzinga · 04/27 20:03
More
No Data
Learn about the latest financial forecast of EXAS. Analyze the recent business situations of Exact Sciences Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
44.44%Buy
5.56%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average EXAS stock price target is 99.44 with a high estimate of 160.00 and a low estimate of 65.00.
High160.00
Average99.44
Low65.00
Current 47.89
EPS
Actual
Estimate
-1.02-0.77-0.51-0.26
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 792
Institutional Holdings: 185.96M
% Owned: 105.69%
Shares Outstanding: 175.95M
TypeInstitutionsShares
Increased
179
14.73M
New
50
745.69K
Decreased
174
7.21M
Sold Out
79
1.24M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.06%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/President/Chief Executive Officer/Director
Kevin Conroy
Chief Financial Officer/Chief Operating Officer/Executive Vice President
Jeffrey Elliott
Senior Vice President/Chief Administrative Officer/General Counsel/Secretary
D. Scott Coward
Senior Vice President
Ana Hooker
Chief Scientific Officer
Graham Lidgard
General Manager
Jake Orville
General Manager
Gisela Paulsen
Independent Director
James Doyle
Independent Director
Pierre Jacquet
Independent Director
Daniel Levangie
Independent Director
Freda Lewis-Hall
Independent Director
Shacey Petrovic
Independent Director
Kathleen Sebelius
Independent Director
Katherine Zanotti
No Data
No Data
About EXAS
Exact Sciences Corporation is a cancer screening and diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) scan.

Webull offers kinds of EXACT Sciences Corporation stock information, including NASDAQ:EXAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXAS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EXAS stock methods without spending real money on the virtual paper trading platform.